Instil Bio, INC

Instil Bio, Inc. stockholders re-elected Class II directors and ratified the appointment of RSM US LLP as the company's independent auditor for 2026.

Instil Bio reported first quarter 2026 results, highlighting a strategic review for potential acquisitions and in-licensing opportunities, with a cash position expected to fund operations beyond 2027.

Instil Bio, Inc. announced on April 1, 2026, the appointment of RSM US LLP as its new independent registered public accounting firm, replacing Deloitte & Touche LLP.

Instil Bio discontinues AXN-2510, pivots to external innovation and M&A, reporting $76.3M cash to fund operations beyond 2027.

Instil Bio's subsidiary, Axion Bio, Inc., has terminated its License and Collaboration Agreement with ImmuneOnco Biopharmaceuticals, effective January 5, 2026, for ex-China rights to AXN-2510 and AXN-27M.

Instil Bio announced its third quarter 2025 financial results and provided a corporate update, highlighting progress in its AXN-2510 clinical trial and an expected cash runway beyond 2026.

Instil Bio's Q1 2026 Form 10-Q filing reveals a net loss of $4.2 million, a significant reduction from the prior year, alongside strategic shifts and ongoing liquidity concerns.

Instil Bio, a clinical-stage biopharmaceutical company, reported a net loss of $13.6 million for Q3 2025, while advancing its lead bispecific antibody candidate, 2510, into a U.S. Phase 1 clinical trial for solid tumors.

Instil Bio, a clinical-stage biopharmaceutical company, reported increased net losses but reduced cash burn from operations, driven by strategic restructuring, a new lead product candidate, and an extended cash runway beyond 2026.

Instil Bio's Q1 2025 results reveal a net loss of $28.2 million, impacted by restructuring and impairment charges related to facility sales and strategic shifts.

Instil Bio reports a net loss of $23.0 million for the third quarter of 2024, alongside updates on its strategic collaborations and financial position.

Instil Bio, Inc., a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ended June 30, 2024, highlighting a net loss of $14.9 million and providing updates on its strategic reprioritization and recent licensing agreement.

Instil Bio, a biotechnology company, has discontinued its lead product candidate AXN-2510 and is now actively seeking to acquire new therapeutic candidates, facing ongoing significant losses and a going concern indicator.

Instil Bio shifts focus to bispecific antibody AXN-2510/IMM2510, reports \$74.1 million net loss for FY2024, and anticipates funding operations beyond 2026.

Instil Bio is closing its UK manufacturing and clinical trial operations, ceasing all ITIL-306 Phase 1 clinical trial activities, and focusing on a collaboration in China for a new autologous FR CoStAR-TIL product.

Director R. Kent McGaughy Jr. was granted 6,500 stock options in Instil Bio, Inc. as part of the company's equity incentive plan.

Director George Matcham was granted 6,500 stock options in Instil Bio, Inc. as part of the company's equity incentive plan.

Director Neil W. Gibson was granted 6,500 stock options in Instil Bio, Inc. as part of the company's equity incentive plan.

Director Gwendolyn Binder was granted 6,500 stock options in Instil Bio, Inc. as part of the company's equity incentive plan.

Instil Bio's CFO and CBO, Sandeep Laumas, executed a pre-planned transaction, exercising stock options and simultaneously selling an equivalent number of common shares.

Instil Bio, Inc. Director Gwendolyn Binder was granted 6,500 stock options with an exercise price of $26.75, vesting over 12 months.

Instil Bio, Inc. has filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held on June 11, 2026.

Instil Bio, Inc. will hold its 2025 Annual Meeting of Stockholders on May 28, 2025, to elect a director and ratify the selection of its independent accounting firm.

Instil Bio, Inc. has filed definitive additional proxy materials with the SEC.

Instil Bio, Inc. will hold its 2025 Annual Meeting of Stockholders on May 28, 2025, to elect a director and ratify the selection of its independent accounting firm.

Instil Bio, Inc. has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

Instil Bio, Inc. will hold its 2024 Annual Meeting of Stockholders on June 13, 2024, to elect directors and ratify the selection of its independent accounting firm.

BML Investment Partners, L.P. has disclosed a 9.5% beneficial ownership stake in Instil Bio, Inc. common stock.

Vivo Capital entities have reported a 4.5% passive ownership stake in Instil Bio, Inc., holding 292,743 shares of common stock.

Boxer Capital Management LLC and Aaron I. Davis, along with affiliated entities, have reported ceasing to beneficially own more than 5% of Instil Bio, Inc.'s common stock, now holding 1.2% of the outstanding shares.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have filed an amended Schedule 13G, reporting a complete divestment of their beneficial ownership in Instil Bio, Inc.'s common stock, reducing their stake to 0.0%.

BML Investment Partners, L.P. and Leonard Braden Michael have jointly disclosed a beneficial ownership of 6.74% in Instil Bio, Inc.'s common stock as of December 31, 2024.